Company Overview - Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on RNA editing for both rare and highly prevalent diseases [3] - The company utilizes a proprietary RNA editing platform to create a portfolio of differentiated programs that enable precise yet transient single base edits [3] - By editing RNA instead of DNA, Korro aims to enhance the precision and tunability of genetic medicines, potentially leading to increased specificity and improved long-term tolerability [3] Upcoming Events - Ram Aiyar, Ph.D., CEO and President of Korro, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025, at 3:45 p.m. PT [1] - Vineet Agarwal, CFO, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also participate in the conference [1] - A live webcast of the presentation will be available on Korro's website, with a replay accessible for 30 days following the event [2]
Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference